Clinical trials: Heart Failure With Preserved Ejection Fraction (HFpEF)
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Preserved Ejection Fraction
Transthyretin Cardiac Amyloidosis in HFpEF
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon…
- Trial name
- NCT03414632
- Testing
- 99mTc-PYP
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Mayo Clinic
Heart Failure, Preserved Ejection Fraction
Precision Rehabilitation for Veterans With (HFpEF)
This study is being completed because there is conflicting information regarding the value of monitored exercise in patients with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT07493915
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia VA Health Care System
Heart Failure
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)
Participants with heart failure with preserved ejection fraction will undergo 12 weeks of cardiac rehabilitation for exercise training (ET) and be randomized to either sodium nitrite or placebo through the training period.
- Trial name
- INABLE (NCT02713126)
- Testing
- Sodium Nitrite, Accelerometer, Cardiac Exercise Training
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barry Borlaug
Heart Failure With Preserved Ejection Fraction (HFPEF)
HFpEF Phenotyping With Echo, Clinical, and Biomarkers
The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two…
- Trial name
- The EPIC-HFpEF (NCT07642921)
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Heart Failure, Diastolic
Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are…
- Trial name
- NCT04603404
- Where
- China
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atrial Fibrillation (AF)
Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study
The proposed pilot study is a prospective, randomized, single-center feasibility study, enrolling 200 patients with symptomatic paroxysmal AF.
- Trial name
- E-TEAM (NCT07385417)
- Testing
- AF Ablation
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Pulmonary; Hypertension, Heart Failure
A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction
This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in healthy adult normal volunteers compared to volunteers with PH-HFpEF in the breakdown…
- Conditions
- Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
- Trial name
- PMED (NCT02980068)
- Testing
- 15N Nitrate, 14N Nitrate
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Gladwin, Mark, MD
Heart Failure With Preserved Ejection Fraction, Hypertension
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired…
- Trial name
- BLOCK HFpEF (NCT04434664)
- Testing
- Amlodipine Besylate, Metoprolol Succinate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Heart Failure With Normal Ejection Fraction
Interleukin-1 Blockade in HF With Preserved EF
Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure Standard treatment for heart failure, show less than ideal results in HFpEF Evidence of systemic inflammation is common in all forms of…
- Trial name
- D-HART2 (NCT02173548)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare…
- Conditions
- HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction, Readmission Rates, Exercise Training
- Trial name
- EMPOWER-HFpEF (NCT07727096)
- Testing
- Exercise-Based Cardiac Rehabilitation, Guideline-Directed Medical Therapy
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure With Preserved Ejection Fraction
Clinical Study of Active Intervention in High-risk HFpEF Patients
Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death.
- Trial name
- NCT06532019
- Testing
- Targeted intervention based on risk factors
- Volunteers
- 924 people
- Sponsor
- Xiangtan Central Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Diastolic
CCM in Heart Failure With Preserved Ejection Fraction
This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have New York Heart Association (NYHA) Class II or III symptoms despite appropriate medication.
- Trial name
- CCM-HFpEF (NCT03240237)
- Testing
- Optimizer SMART
- Where
- 17 sites in Australia, Czechia and 6 more
- Volunteers
- 47 people
- Sponsor
- Impulse Dynamics
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Atrial Fibrillation (AF), Hart Failure
Heart Failure Biomarkers
Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE.
- Trial name
- BIOHF (NCT06616038)
- Testing
- Data collection
- Where
- 2 sites in Italy
- Volunteers
- 114 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
HFpEF - Heart Failure With Preserved Ejection Fraction
Role of Colchicine as Anti-Inflammatory Therapy in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a condition associated with high morbidity and mortality. Chronic low-grade inflammation plays a key role in its progression, yet few treatments specifically target this…
- Trial name
- CO-HFpEF (NCT06837623)
- Testing
- Colchicine Tablets
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Cairo University
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center